Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cyclandelate is a small molecule vasodilator used to treat conditions associated with poor blood circulation such as claudication (pain caused by too little blood flow), arteriosclerosis (hardening of the arteries), Raynaud's disease (a condition causing decreased blood flow to extremities), and nighttime leg cramps. It has also been investigated for migraine prophylaxis. Cyclandelate acts as a direct-acting smooth muscle relaxant that dilates peripheral blood vessels by antagonizing calcium ion channel function in vascular smooth muscle. This leads to relaxation of veins and arteries and improved blood flow[1][2][6]. The drug was formerly distributed in the United States but was discontinued by Wyeth-Ayerst in April 1997; it remains approved in some European countries[1][2]. It is administered orally.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Cyclandelate.